Trials / Completed
CompletedNCT03198130
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)
An Exploratory Tumor Biopsy-Driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Immunomodulatory Treatment-Naïve Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck Receiving REGN2810 (Anti-PD-1)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to compare the relationship of patient response to treatment to changes in tumor microenvironment.
Conditions
- Recurrent Squamous Cell Carcinoma of Head
- Recurrent Squamous Cell Carcinoma of Neck
- Metastatic Squamous Cell Carcinoma of Head
- Metastatic Squamous Cell Carcinoma Neck
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN2810 | Intravenous (IV) use |
Timeline
- Start date
- 2017-07-03
- Primary completion
- 2019-06-27
- Completion
- 2020-02-21
- First posted
- 2017-06-23
- Last updated
- 2020-03-19
Locations
6 sites across 2 countries: South Korea, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03198130. Inclusion in this directory is not an endorsement.